Intraday Movement and Market Context
On 8 December 2025, Concord Biotech’s stock touched an intraday low of Rs 1364, reflecting a 2.85% decline for the day. This underperformance was more pronounced than the Pharmaceuticals & Biotechnology sector, where the stock lagged by 1.84%. The broader market, represented by the Sensex, opened flat but later declined by 0.54%, closing at 85,251.69 points. Despite the Sensex trading above its 50-day moving average and remaining just 1.06% below its 52-week high of 86,159.02, Concord Biotech’s share price remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.
Long-Term Price Performance
Over the past year, Concord Biotech’s stock has recorded a return of -37.21%, a stark contrast to the Sensex’s positive 4.35% return during the same period. The stock’s 52-week high was Rs 2451.65, indicating a substantial decline from its peak. This downward trajectory has persisted over multiple time frames, with the stock also underperforming the BSE500 index over the last three years, one year, and three months.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Metrics Reflecting Recent Performance
Concord Biotech’s financial data over recent quarters and years reveals subdued growth and pressures on profitability. The company’s operating profit has shown a compound annual rate of change of -0.48% over the last five years, indicating limited expansion in core earnings. The latest quarterly Profit Before Tax (PBT) stood at Rs 72.33 crores, representing a decline of 32.1% compared to the previous four-quarter average.
Operating cash flow for the year is reported at Rs 244.52 crores, marking the lowest level in recent periods. The Profit After Tax (PAT) for the latest six months is Rs 107.64 crores, reflecting a contraction of 30.7%. These figures underscore the challenges in maintaining earnings momentum amid a competitive and evolving pharmaceutical landscape.
Valuation and Efficiency Indicators
The company’s return on equity (ROE) is recorded at 17.7%, which is relatively high and suggests efficient utilisation of shareholder funds. However, this is accompanied by a price-to-book value ratio of 8, indicating a valuation that may be considered expensive relative to book value. Despite this, the stock’s valuation remains broadly in line with historical averages observed among its peers in the Pharmaceuticals & Biotechnology sector.
Debt and Shareholding Structure
Concord Biotech maintains a low debt profile, with an average debt-to-equity ratio of zero, reflecting a conservative capital structure. The majority of the company’s shares are held by promoters, indicating concentrated ownership and potential alignment of interests with long-term company performance.
Holding Concord Biotech from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector and Market Comparison
While Concord Biotech’s stock has faced downward pressure, the Pharmaceuticals & Biotechnology sector as a whole has experienced mixed performance. The sector’s broader indices have not mirrored the steep decline seen in Concord Biotech’s shares, which suggests company-specific factors have contributed to the stock’s recent lows. The Sensex’s resilience, trading above key moving averages and near its 52-week high, further highlights the divergence between the company’s share price and overall market trends.
Summary of Key Price and Performance Indicators
To summarise, Concord Biotech’s stock price has moved from a 52-week high of Rs 2451.65 to a new low of Rs 1364, representing a significant reduction in market value. The stock’s underperformance relative to the Sensex and its sector peers is reflected in its negative returns over the past year and subdued profit metrics. The company’s financial indicators show a combination of high management efficiency and conservative leverage, but these have not translated into positive share price momentum in recent times.
Conclusion
Concord Biotech’s fall to its 52-week low underscores the challenges faced by the company in sustaining growth and profitability amid a competitive pharmaceutical environment. The stock’s current valuation and financial metrics provide a detailed picture of its recent performance, while the broader market context highlights the divergence between the company’s share price and overall market trends. Investors and market participants will continue to monitor the company’s financial disclosures and sector developments for further insights.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
